Navigation Links
Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
Date:3/29/2011

, after which it plans to conduct the necessary studies required to initiate clinical trials later this year.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novogen and Marshall Edwards Sign Asset Purchase Agreement
2. Marshall Edwards CEO to Present at Lazard Capital Markets Healthcare Conference
3. Marshall Edwards CEO to Present at JMP Securities Healthcare Conference
4. Nobel Prize Winner Robert Edwards: A Personal Memoir by the Only American Physician to Participate in Developing IVF
5. Protege of Nobel Prize Winner Robert Edwards Carries on his IVF Legacy
6. Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
7. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
8. Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
9. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
10. Reportlinker Adds Quantum Dots: Technologies and Global Markets
11. Neogen Reports 27% Increase in Quarterly Net Income
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... sciences company that develops and commercializes proprietary technologies and ... and operational results for the fiscal first quarter ended ... are in Canadian dollars (CAD), unless otherwise stated. ... win new business from our existing customers and add ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015 DuPont ... growth priorities driven by key research advancements and product ... at today,s Bank of America Merrill Lynch 2015 Global ... the challenge of building grain supplies the last two ... continue at the pace of the last decade, when ...
(Date:2/26/2015)... -- The healthcare landscape is rapidly and radically changing. To ... host its 20 th Anniversary Medical Technologies 2015: ... 10, at the Hilton San Diego Resort and Spa in ... event is a platform for global medical devices, diagnostics, life ... how to succeed in an uncertain future. Participants ...
(Date:2/26/2015)... February 26, 2015 Innovation is ... emerging from unexpected parts of the world and ... From agriculture to manufacturing to health care, disruption ... environmental realities and socio-political trends shake the foundations ... key ingredient for CEOs to survive the next ...
Breaking Biology Technology:SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... NV,(Euronext Brussels: THR), a biotechnology company focused on ... is today issuing a,business update for the nine ... De Haes, CEO of ThromboGenics, commenting on today,s,announcement, ... anticipated. We are now working hard to prepare ...
... 6 AmeriCares has,awarded its annual "Power ... global biotechnology, medical device and specialty pharmaceutical,company. ... Distribution,Management Association,s (HDMA) Annual Leadership Forum in ... award was created by AmeriCares and HDMA ...
... Calif., Nov. 6 ( http://www.amdl.com ),AMDL, Inc. ... with major operations in China and the U.S., ... Douglas MacLellan will present at,Rodman & Renshaw,s Annual ... 2008 at the New York Palace Hotel in ...
Cached Biology Technology:ThromboGenics N.V.: Business Update 2ThromboGenics N.V.: Business Update 3ThromboGenics N.V.: Business Update 4ThromboGenics N.V.: Business Update 5ThromboGenics N.V.: Business Update 6ThromboGenics N.V.: Business Update 7ThromboGenics N.V.: Business Update 8AmeriCares Presents 'Power of Partnership' Award to Baxter 2AmeriCares Presents 'Power of Partnership' Award to Baxter 3AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008 2
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... Dr. Jian Han, faculty investigator at the HudsonAlpha ... response, molecular-level assay for swine flu, the current strain ... test, which can confirm swine flu in less than ... panel made available by Diatherix Laboratories. The panel ...
... but on the riseand infants are the most common ... aims to raise awareness of this often overlooked crime. ... of Pharmacy, and recent graduate Brian Ferslew examined seven ... deaths due to homicidal poisoninga figure that corresponds to ...
... University researchers, along with scientists at Washington University in ... by studying the brain while it is at rest. ... new tools for diagnosing mental health disorders and monitoring ... published in the journal the Public Library of ...
Cached Biology News:HudsonAlpha investigator develops rapid response swine flu test 2Study finds homicidal poisoning rising, more likely in infants and elderly 2OHSU researchers study the idling brain 2
Leptin Receptor Polyclonal Ab 100 ug purified rabbit anti-mouse Leptin Receptor. Tested in Western blotting....
... AccuPrime™ Pfx DNA Polymerase is ... fragments for downstream applications such as ... is provided by a proprietary enzyme ... Pyrococcus sp. with proofreading (3'Cut Site5' ...
... amino acid polypeptide sequence corresponding to Tyr89 ... Produced by activation of a recombinant soluble ... periplasm. SPECIFIC ACTIVITY:The specific activity of ... where 1 U is the activity that ...
... Grade Thrombin is a highly purified preparation ... with appropriate vectors. The preparation is functionally ... is free of detectable contaminating proteases. Prepared ... by certified tests to be negative for ...
Biology Products: